Immunovant, Inc. IMVT Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s interest income (expense), nonoperating?
- Immunovant, Inc. (IMVT) reported interest income (expense), nonoperating of $8.06M in Q1 2026.
- How has Immunovant, Inc.'s interest income (expense), nonoperating changed year-over-year?
- Immunovant, Inc.'s interest income (expense), nonoperating increased by 17.0% year-over-year, from $6.89M to $8.06M.
- What is the long-term trend for Immunovant, Inc.'s interest income (expense), nonoperating?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s interest income (expense), nonoperating has grown at a 49.5% compound annual growth rate (CAGR), from $7.58M to $25.33M.